Expanding Genetic Access for Prostate Cancer Survivors

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18-80
SponsorGeorgetown University

About this trial

The goal of this study is to increase genetic education and genetic testing for hereditary cancer risk among prostate cancer survivors. The study will:

Test the effectiveness of a digital guide (DG+) vs. print guide (Print+) vs. enhanced usual care (EUC) on engagement in genetic education and uptake of genetic testing.

Evaluate the impact of the DG+ vs. Print+ vs. EUC on the process that participants use to make decisions and evaluate effects on well-being (also called psychosocial outcomes).

Explore the ways (methods) that influence how participants experience the intervention.

The main questions this study aims to answer are: which group - the digital guide (DG+) group, print (Print+) group or the EUC group - is more likely to request genetic testing and which group is more likely to get (engage with) genetic education.

Participants will be randomly assigned to either the digital guide (DG+) group, the print guide (Print+) group or EUC group. Each group will receive genetic education and have an opportunity to request genetic testing. Researchers will compare the three groups to determine which is most most likely to complete genetic testing (GT) and which group engages more with genetic education.

Eligibility criteria

Qualifiers

18-80 years of age

At least 6-months post diagnosis with prostate cancer

Have not had genetic testing for hereditary cancer

Have received care at one of the participating sites in the prior five years

Disqualifiers

Do not speak English

Unable to access the Internet

Have previously undergone germline genetic testing for hereditary cancer risk or previously had genetic counseling (GC) and declined genetic testing (GT)

Are unable to provide informed consent

Trial design

Treatments tested in this trial

  • Print Genetic Education Guide
  • Digital Guide Genetic Education Guide
  • Enhanced Usual Care

Treatment groups

500 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Georgetown University

Lead sponsor

National Cancer Institute (NCI)

Collaborator

Rutgers University

Collaborator